Kevin C. Johnson, Ph.D.
Postdoctoral Associate
Farmington, CT
Leverages genomic technologies to investigate brain tumor biology and disease evolution.
Farmington, CT
Leverages genomic technologies to investigate brain tumor biology and disease evolution.
2016 – present Postdoctoral Research Fellow
The Jackson Laboratory for Genomic Medicine
2011 – 2016 Ph.D., Experimental and Molecular Medicine
Dartmouth College
2007 – 2011 B.S., Food Science and Technology,
University of Massachusetts – Amherst
2016 Neukom Prize for Outstanding Graduate Research in Computational Science
Albert J. Ryan Predoctoral Fellowship
The Search Magazine Article
September 18, 2017
Professor Roel Verhaak, Ph.D., is focused on the analysis of cancer genomics data to improve our understanding of cancer biology.
The Search Magazine Article
May 23, 2016
Computational biologist Jeffrey Chuang applies the power of big data to big problems in biology — from how cancer cells evolve to how computational tools and knowledge can be broadly shared.
Learn how monoclonal antibodies (mAbs) can target intracellular oncoproteins in mice, offering new directions for antibody-based cancer therapies.
Learn how the NSG model is revolutionizing cancer research, allowing the engraftment of patient-derived tumors such as melanoma, leukemia and lung tumors.
Blog Post
March 28, 2016
The world’s biomedical research community will continue to depend on the laboratory mouse as the premier model for human biology and disease for decades to come, even as cell lines, computer simulations and other technologies come online.
Blog Post
September 02, 2015
Everything you need to know about next generation genotyping techniques that JAX uses to genotype mice in our repository. From Melt curve analysis to endpoint assays to distinguish wt, heterozygous and homozygous mutant mice.
New research from the University of California Davis and The Jackson Laboratory provides more evidence that patient-derived xenografts (PDXs), human tissues implanted in immunocompromised mice, can provide powerful insight into cancer mechanisms and therapies.
Two FcRn-“humanized” mouse models developed by JAX Professor Derry Roopenian facilitate the development of preclinical therapeutic antibodies.